Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location.
Julia D LabadieTabitha A HarrisonBarbara L BanburyEfrat L AmtaySonja BerndHermann BrennerDaniel D BuchananPeter T CampbellYin CaoAndrew T ChanJenny Chang-ClaudeDallas R EnglishJane C FigueiredoSteven J GallingerGraham G GilesMarc J GunterMichael HoffmeisterLi HsuMark E JenkinsYi LinJonathan BeesleyVictor MorenoNeil MurphyShuji OginoAmanda I PhippsLori C SakodaMartha L SlatteryMelissa C SoutheyWei SunStephen N ThibodeauBethany Van GuelpenSyed H ZaidiUlrike PetersPolly A NewcombPublished in: JNCI cancer spectrum (2020)
We observed a strong inverse association between HT use and overall CRC risk, which may predominantly reflect a benefit of HT use for tumors arising through the adenoma-carcinoma and alternate pathways as well as distal colon and rectal tumors.